These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 7518514

  • 1. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
    Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS.
    J Pharmacol Exp Ther; 1994 Jul; 270(1):310-8. PubMed ID: 7518514
    [Abstract] [Full Text] [Related]

  • 2. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT.
    J Pharmacol Exp Ther; 1994 Jul; 270(1):319-28. PubMed ID: 7913497
    [Abstract] [Full Text] [Related]

  • 3. Characterization of [3H]ABT-418: a novel cholinergic channel ligand.
    Anderson DJ, Williams M, Pauly JR, Raszkiewicz JL, Campbell JE, Rotert G, Surber B, Thomas SB, Wasicak J, Arneric SP.
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1434-41. PubMed ID: 7791118
    [Abstract] [Full Text] [Related]

  • 4. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.
    Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, Piattoni-Kaplan M, Molinari E, Campbell JE, McKenna DG, Gunn DE, Lin NH, Ryther KB, He Y, Holladay MW, Wonnacott S, Williams M, Arneric SP.
    J Pharmacol Exp Ther; 1997 Oct; 283(1):235-46. PubMed ID: 9336329
    [Abstract] [Full Text] [Related]

  • 5. Regulation of human alpha4beta2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways.
    Gopalakrishnan M, Molinari EJ, Sullivan JP.
    Mol Pharmacol; 1997 Sep; 52(3):524-34. PubMed ID: 9281615
    [Abstract] [Full Text] [Related]

  • 6. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
    Gopalakrishnan M, Monteggia LM, Anderson DJ, Molinari EJ, Piattoni-Kaplan M, Donnelly-Roberts D, Arneric SP, Sullivan JP.
    J Pharmacol Exp Ther; 1996 Jan; 276(1):289-97. PubMed ID: 8558445
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist.
    Sacaan AI, Reid RT, Santori EM, Adams P, Correa LD, Mahaffy LS, Bleicher L, Cosford ND, Stauderman KA, McDonald IA, Rao TS, Lloyd GK.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):373-83. PubMed ID: 8996218
    [Abstract] [Full Text] [Related]

  • 8. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.
    Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, Piattoni-Kaplan M, McKenna DG, Wasicak JT, Holladay MW, Williams M, Arneric SP.
    J Pharmacol Exp Ther; 1998 May; 285(2):777-86. PubMed ID: 9580626
    [Abstract] [Full Text] [Related]

  • 9. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.
    Lin NH, Gunn DE, Ryther KB, Garvey DS, Donnelly-Roberts DL, Decker MW, Brioni JD, Buckley MJ, Rodrigues AD, Marsh KG, Anderson DJ, Buccafusco JJ, Prendergast MA, Sullivan JP, Williams M, Arneric SP, Holladay MW.
    J Med Chem; 1997 Jan 31; 40(3):385-90. PubMed ID: 9022806
    [Abstract] [Full Text] [Related]

  • 10. Anxiolytic-like effects of the novel cholinergic channel activator ABT-418.
    Brioni JD, O'Neill AB, Kim DJ, Buckley MJ, Decker MW, Arneric SP.
    J Pharmacol Exp Ther; 1994 Oct 31; 271(1):353-61. PubMed ID: 7965735
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.
    Arneric SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW, Briggs CA, Donnelly-Roberts D, Radek RJ, Marsh KC, Kyncl J.
    Alzheimer Dis Assoc Disord; 1995 Oct 31; 9 Suppl 2():50-61. PubMed ID: 8534424
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacological characterization of neuronal acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices.
    Sacaan AI, Dunlop JL, Lloyd GK.
    J Pharmacol Exp Ther; 1995 Jul 31; 274(1):224-30. PubMed ID: 7542334
    [Abstract] [Full Text] [Related]

  • 17. N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors.
    Wilkins LH, Grinevich VP, Ayers JT, Crooks PA, Dwoskin LP.
    J Pharmacol Exp Ther; 2003 Jan 31; 304(1):400-10. PubMed ID: 12490617
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.